PubMed Health⌕ Search

Biomedical subjects

I Holló

Publications and source records attributed to I Holló.

At least 19 recordsLinked to original sources
PubMed1992

[Treatment of postmenopausal osteoporosis with low doses of calcitonin and a calcitonin-anabolic combination].

Menopausal osteoporotic women (age: 49-69, mean: 59.5 years) with crush fractures of the spine were treated with low doses of calcitonin (Miacalcic, 350 U/month), or with calcitonin + anabolic steroid (Retabolil, 50 mg/month). Efficacy of the therapy was controlled by single foton absorptiometry of midshaft and distal radius, by X-ray morphometry and by registering new crush fractures of the spine. Calcitonin monotherapy stopped further bone loss for two years, but at the end of the third year both absorptiometric values, as well as the radiomorphometrical index of the lumbar spine decreased significantly. In patients on calcitonin+anabolic steroid the decrease was just significant and only at radius midshaft, while at the other measured sites it was not. Two new crush fractures per 1396 patient-months occurred. Intermittent administration of low-dose calcitonin, especially together with an anabolic steroid seems to be a safe and effective therapy in established osteoporosis.

Aged↗
PubMed1992

[Spinal and appendicular osteoporosis in streak gonad syndrome. Photon absorptiometric and roentgen-morphometric studies].

Patterns of bone loss in the axial and the appendicular skeleton were studied in 48 women with streak gonad syndrome (age: between 14-38 years, mean: 25.5 years). Bone mineral content was measured in vivo at the lumbar spine and right femoral neck by dual photon absorptiometry and at the midradius and distal radius by single photon absorptiometry. The bone mineral status of 20 patients was evaluated by radiomorphometrical indices of the metacarpals, femorals and lumbar spine, too. Mean bone mineral content and radiomorphometrical indices were significantly lower in patients with streak gonad syndrome than in age-matched normal subjects at all three scanning sites. The patients lost cortical and trabecular bone mineral content at the same rate, suggesting that bone loss in streak gonad syndrome is a generalized phenomenon. In spite of serious bone loss osteoporotic fractures were not observed in the patients, in contrast to patients with pathological post-menopausal osteoporosis having equal degree of bone deficiency. The authors did not find any relationship between the occurrence of osteoporosis and the karyotype of the patients. It is suggested that the osteoporosis in streak gonad syndrome--at least after puberty--is a consequence of gonadal hormone deficiency.

Absorptiometry, Photon↗
PubMed1992

Three-year calcitonin combination therapy for postmenopausal osteoporosis with crush fractures of the spine.

Forty-five postmenopausal osteoporotic women with at least one osteoporotic vertebral crush fracture were randomized into three treatment groups. Each patient was on calcitonin, 50 U, on alternate days for 2 weeks monthly (350 U/month), and 500 mg/day oral calcium supplementation. In group II, this therapy was supplemented with phosphate (750 mg/day), and in group III, norandrostenolone decanoate (50 mg/month) was added to the calcitonin+calcium therapy. Bone mineral content, by single photon absorptiometry, of the radius midshaft and distal site (3 cm), as well as the lumbar and metacarpal radiomorphometrical indices were estimated seminannually. The therapeutic trial lasted 36 months except in the phosphate supplementation group, where, due to unfavorable results, treatment was discontinued after 24 months. Calcitonin practically prevented further bone loss for 24 months even in this relatively small and intermittent dosage. Phosphate supplementation was without benefit; however, according to the majority of the examined parameters, combination of calcitonin with the anabolic steroid norandrostenolone decanoate extended efficacy up to 36 months. This latter combination seems to be a promising, relatively inexpensive therapeutic regimen in the treatment of established postmenopausal osteoporosis.

Aged↗
PubMed1991

[Mean value of bone mineral content in Hungary measured by dual-photon absorptiometry].

Bone mineral content and density of the lumbar spine and femoral neck was measured by dual energy X-ray absorptiometry in normal volunteers (89 women, 77 men) in different age groups. Peak values in both sexes occurred in the 3rd decade and are about 25% higher in men than those in women. In women the bone loss begins around 40 years at lumbar spine and also at the femoral neck. The rate of bone loss in the 6th decade--according to the menopause--significantly accelerates. The diminution in the 8th decade is higher again. In men the decrease of the lumbar spine density is also significant in connection with the ageing process, but the rate of the bone loss is slower, than in women. The femoral neck density and mineral content values begin to decrease at the 4th decade. The decrease of bone mineral content and density of femoral neck are equivalent in both sexes but some difference exists in the velocity. The data were compared with West-european values. The values of the femoral neck are lower, while those of the lumbar spine in the 5th decade in the female are higher in the Hungarian population. The reason of this difference may be the consequence of the obesity of the Hungarian female population.

Absorptiometry, Photon↗
PubMed1991

[Decreased serum osteocalcin level in non-alcoholic and alcoholic chronic liver diseases].

Serum level of osteocalcin (OC) is believed to be a specific biochemical parameter of bone formation. Decreased serum OC has been reported in alcohol-intoxicated subjects, in patients with primary biliary cirrhosis and in patients with chronic alcoholic liver disease. The question was, whether lower OC level could be detected in patients with nonalcoholic and non-cholestatic chronic liver disease. The serum OC was measured by RIA developed in our laboratory. Results were compared to age and sex matched controls. Decreased OC level was found in 35 out of 47 (74%) patients with non-alcoholic and non-cholestatic liver disease as chronic persistent hepatitis, chronic active hepatitis, fatty liver and cirrhosis, in 21 out of 26 (80%) patients with alcoholic liver disease and in 8 out of 15 (53%) primary biliary cirrhosis. None of the patients had elevated value. There was no correlation between the decreased OC level and the duration or severity of the liver disease and the laboratory parameters as bilirubin, AST, ALT, alkaline phosphatase, albumin, prothrombin, and serum 25-OH-D3 vitamin level. Decreased OC was found also in the patients without cirrhosis. The possible causes are discussed. Relying upon these findings it is supposed that chronic liver disease by itself can influence the osteoblast activity also by some unknown mechanism.

Bone Diseases, Metabolic↗
PubMed1991

[Proposal for the management of primary care for patients with suspected osteoporosis and patients with actual osteoporosis within the framework of the Hungarian health care system].

The author at first gives the definition of various facts which are important in the concept of metabolic bone disease from the point of view of direct practice. Then he summarizes the clinical signs of severe or mild osteoporosis, as well as the factors, suggesting osteoporosis in a certain patient. The objective methods, used in the diagnosis of calcipenic osteopathy are also reviewed from the simple X-ray films to the various osteodensitometric methods. He points to the simple signs, which give the possibility to identify or to differentiate among the various forms of calcipenic osteopathy. Then he introduces the forms of therapy. Finally, a schematic figure is also given, which includes his suggestion on the management of patients with suspected or developed osteoporosis, presuming the average Hungarian possibilities.

Adult↗
PubMed1991

Serum bone Gla protein in streak gonad syndrome.

Osteoporosis is one of the most common complications of streak gonad syndrome (SGS), however its pathogenesis is still unclear. Bone Gla protein (BGP) has been found to be a serum marker of bone turnover in various metabolic disease states. In the present study serum BGP and alkaline phosphatase (AP) were measured in 13 osteoporotic patients with SGS and in 56 healthy women. Mean (+/- SD) serum BGP levels were normal (7.5 +/- 2.0 ng/ml) in seven patients who had been on estrogen-progestin replacement therapy and became significantly elevated (P less than 0.001) 2 and 3 months after discontinuation of the treatment (15.3 +/- 2.3 and 13.2 +/- 1.0 ng/ml, respectively). Mean (+/- SD) serum AP (207 +/- 65 U/l) showed significant increases (P less than 0.05) 2 months after withdrawal of hormonal substitution (287 +/- 74 U/l). Mean (+/- SD) serum BGP (15.4 +/- 3.5) and AP (287 +/- 49) levels were significantly higher (P less than 0.001 and less than 0.05, respectively) in six patients with SGS who had not been on hormonal substitution. These findings are consistent with those obtained in postmenopausal women suffering from "high remodelling osteoporosis" and suggest that bone turnover in osteoporotic patients with SGS is increased and the skeletal loss is a consequence of accelerated bone loss rather than decreased bone formation.

Adult↗
PubMed1989

Androgens and bone mineral content in patients with subtotal thyroidectomy for benign nodular disease.

To investigate the influence of thyroid surgery on the skeleton and different hormones a well characterized patient group of 24 women was selected who had undergone subtotal thyroidectomy for euthyroid benign nodular disease and remained euthyroid after the operation. Bone mineral content was determined in lumbar vertebrae, femoral neck and radius by dual and single photon absorptiometry. The serum levels of calcitonin, dehydroepiandrosterone, dehydroepiandrosterone-sulphate, androstenedione, total testosterone, cortisol and 25-hydroxyvitamin D were measured. A control group was created of 48 healthy female subjects. No reduction in bone mass was observed at the measured sites compared to appropriate controls. Beside normal bone mineral content significantly elevated serum levels of dehydroepiandrosterone (27.4 +/- 10.4 vs. 20.8 +/- 6.9 nmol/l) and androstenedione 9.3 +/- 3.3 vs. 6.6 +/- 2.2 nmol/l) were found without any clinical sign of androgen excess. There was no correlation between bone mineral content and these androgen levels. The serum calcitonin levels of all patients were low. With regard to the previously reported interactions among androgen, calcitonin and bone metabolism, our results raise the possibility of a relationship between higher androgen levels and preserved bone mass in these patients, while normal bone mineral content and calcitonin deficiency in these patients does not inevitably indicate that calcitonin does not affect bone tissue in adults.

Adenoma↗
PubMed1989

Changes with aging in the bone mineral content of the lumbar spine and femoral neck in healthy women in Hungary.

The bone mineral content (BMC) of the lumbar spine and femoral neck was studied in relation to aging in healthy Hungarian women by duel photon-absorptiometric method. The data were compared with North-American and West-European values. The Hungarian values are lower than these for reported from North-America or France, but similar to the BMC values for Sweden. The observed vertebral and femoral bone loss could be well represented by cubic equations. The acceleration of bone loss seems to begin around 40 years. The rate of bone loss was similar to the published values but the decrease in bone loss in the 6th and 7th decades was more suggestive. With regard to the fracture-threshold below which the risk for non-traumatic fractures of vertebrae increases, about 60% of Hungarian women at age 50-59 and about 84% at age 60-69 are considered to be at risk. It is concluded that geographical and habitual differences might be important factors in the development and change of BMC for different populations.

Adult↗